Drug Profile

Research programme: Chronic urticaria therapeutics - Enanta Pharmaceuticals

Latest Information Update: 12 Aug 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Enanta Pharmaceuticals
Class Skin disorder therapies; Small molecules
Mechanism of Action Proto-oncogene protein c-kit inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Chronic urticaria

Most Recent Events

05 Aug 2024 Enanta Pharmaceuticals plans to select a leading clinical candidate for Chronic-urticaria from this research programme by Q4 2024
06 May 2024 Preclinical trials in Chronic-urticaria in USA (PO) before May 2024
06 May 2024 Pharmacodynamics and pharmacokinetics data from the preclinical studies in Chronic-urticaria released by Enanta Pharmaceuticals

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com